Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel steroidal pure antiestrogens.

J Bowler1, T J Lilley, J D Pittam

  • 1Research Department 1, ICI Pharmaceuticals, Macclesfield, Cheshire, UK.

Steroids
|July 1, 1989
PubMed
Summary

New steroidal estrogen antagonists derived from estradiol were discovered. These potent compounds exhibit no intrinsic estrogenicity, offering potential therapeutic applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metal hypersensitivity in total joint replacement: review of the literature and practical guidelines for evaluating prospective recipients.

Orthopedics·2014
Same author

The reversible cerebral vasoconstriction syndrome in association with venlafaxine and methenamine.

BMJ case reports·2013
Same author

Birth of a biome: insights into the assembly and maintenance of the Australian arid zone biota.

Molecular ecology·2008
Same author

Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.

Endocrine-related cancer·2005
Same author

Inhibitors of growth factor signalling.

Endocrine-related cancer·2005
Same author

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.

Endocrine-related cancer·2004

Area of Science:

  • Endocrinology
  • Medicinal Chemistry

Background:

  • Estrogen antagonists are crucial for managing hormone-dependent diseases.
  • Developing selective estrogen receptor modulators (SERMs) with minimal intrinsic activity is a key research area.

Purpose of the Study:

  • To discover and characterize novel steroidal estrogen antagonists.
  • To investigate structure-activity relationships of estradiol derivatives.

Main Methods:

  • Synthesis of estradiol derivatives with amidoalkyl side chains at the 7 alpha-position.
  • Uterotrophic and anti-uterotrophic assays in rats to assess estrogenicity and antagonist activity.

Main Results:

  • A series of steroidal compounds with potent estrogen antagonist activity were identified.
  • The most effective compounds were N-n-butyl-N-methyl-11-(3,17 beta-dihydroxyestra- 1,3,5(10)-trien-7 alpha-yl) undecanamide and N-2,2,3,3,4,4,4-heptafluorobutyl-N-methyl-11-(3,17 beta-dihydroxyestra- 1,3,5(10)-trien-7 alpha-yl) undecanamide.
  • These compounds demonstrated no intrinsic estrogenicity in vivo.

Conclusions:

  • Novel estradiol derivatives function as potent, non-estrogenic estrogen antagonists.
  • The 7 alpha-position modifications are critical for achieving antagonist activity.
  • These findings provide a basis for developing new therapeutic agents targeting estrogen pathways.

Related Experiment Videos